Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Opening stock page...
Fetching company snapshot, pricing, and intelligence.
AI confidence 70% · prior close shown (market closed)
Atrium Therapeutics, Inc. shows accelerating business momentum based on AlphaOS pipeline evidence, with mixed management execution.
Why it matters: Milestone Payment Received.
Watch: Clinical trial success risk for ATR 1072 and ATR 1086.
3 signals not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 0d ago
Reported figures for Atrium Therapeutics, Inc. — research only, not investment advice.
Theme: Clinical Development
Updated
What happened recently for Atrium Therapeutics, Inc. (RNA) — events, not interpretation.
Research & analysis only — not investment advice.
Investment snapshot
Prior close
$12.33
Market cap
$210.91M
Profitable
No
Revenue $19.64M
Net income
$-16.63M
FY Jul 18, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for Atrium Therapeutics, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Connected companies and research pages from the AlphaOS knowledge graph.
Follow Atrium Therapeutics, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.